Platelet‐derived apoptotic vesicles ameliorate nonalcoholic fatty liver disease by regulating lipid metabolism via apolipoprotein A‐II
Abstract Nonalcoholic fatty liver disease (NAFLD) encompasses a broad range of conditions, commencing with simple steatosis and progressing to non‐alcoholic steatohepatitis, with the possibility of further deterioration into fibrosis, cirrhosis, and ultimately, hepatocellular carcinoma. Unfortunatel...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley-VCH
2025-01-01
|
| Series: | Interdisciplinary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/INMD.20240059 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586445433339904 |
|---|---|
| author | Yuhe Jiang Yike Liao Zeying Wang Lei Zhu Yunsong Liu Ping Zhang Yuan Zhu Wenyue Li Yongsheng Zhou Xiao Zhang |
| author_facet | Yuhe Jiang Yike Liao Zeying Wang Lei Zhu Yunsong Liu Ping Zhang Yuan Zhu Wenyue Li Yongsheng Zhou Xiao Zhang |
| author_sort | Yuhe Jiang |
| collection | DOAJ |
| description | Abstract Nonalcoholic fatty liver disease (NAFLD) encompasses a broad range of conditions, commencing with simple steatosis and progressing to non‐alcoholic steatohepatitis, with the possibility of further deterioration into fibrosis, cirrhosis, and ultimately, hepatocellular carcinoma. Unfortunately, there is currently no approved medication for treating NAFLD‐associated liver steatosis. This underscores the need for improved therapeutic approaches that can modulate lipid metabolism and halt the transition from liver steatosis to chronic liver disease. Our previous studies have demonstrated that apoptotic vesicles (apoVs), which are produced during apoptosis, show great potential in regulating liver homeostasis. However, whether they can ameliorate NAFLD is unknown. In our research, apoVs derived from platelets (PLT‐apoVs) as well as apoVs derived from mesenchymal stem cells (MSC‐apoVs) were used to treat NAFLD. The results showed that PLT‐apoVs exhibited superior effects in diminishing lipid accumulation in liver induced by high‐fat diet than MSC‐apoVs. Through proteomic analysis, we defined and validated apolipoprotein A‐II (APOA2) as a regulator for apoV‐mediated MSC adipogenesis, which could be used as a target to enhance apoV therapeutic potential in the lipid metabolism biomedical field. Owing to the higher expression of APOA2, PLT‐apoVs showed better therapeutic effects than MSC‐apoVs. Our results pave the way to apoV‐based therapy for NAFLD. |
| format | Article |
| id | doaj-art-d6cadf2fbcf34a91a98d5de13d7f0f9d |
| institution | Kabale University |
| issn | 2832-6245 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley-VCH |
| record_format | Article |
| series | Interdisciplinary Medicine |
| spelling | doaj-art-d6cadf2fbcf34a91a98d5de13d7f0f9d2025-01-25T17:57:32ZengWiley-VCHInterdisciplinary Medicine2832-62452025-01-0131n/an/a10.1002/INMD.20240059Platelet‐derived apoptotic vesicles ameliorate nonalcoholic fatty liver disease by regulating lipid metabolism via apolipoprotein A‐IIYuhe Jiang0Yike Liao1Zeying Wang2Lei Zhu3Yunsong Liu4Ping Zhang5Yuan Zhu6Wenyue Li7Yongsheng Zhou8Xiao Zhang9Department of Prosthodontics Peking University School and Hospital of Stomatology National Center of Stomatology National Clinical Research Center for Oral Disease National Engineering Research Center of Oral Biomaterials and Digital Medical Devices Beijing Key Laboratory of Digital Stomatology Research Center of Engineering and Technology for Computerized Dentistry Ministry of Health NMPA Key Laboratory for Dental Materials Beijing ChinaDepartment of Prosthodontics Peking University School and Hospital of Stomatology National Center of Stomatology National Clinical Research Center for Oral Disease National Engineering Research Center of Oral Biomaterials and Digital Medical Devices Beijing Key Laboratory of Digital Stomatology Research Center of Engineering and Technology for Computerized Dentistry Ministry of Health NMPA Key Laboratory for Dental Materials Beijing ChinaDepartment of Prosthodontics Peking University School and Hospital of Stomatology National Center of Stomatology National Clinical Research Center for Oral Disease National Engineering Research Center of Oral Biomaterials and Digital Medical Devices Beijing Key Laboratory of Digital Stomatology Research Center of Engineering and Technology for Computerized Dentistry Ministry of Health NMPA Key Laboratory for Dental Materials Beijing ChinaDepartment of Prosthodontics Peking University School and Hospital of Stomatology National Center of Stomatology National Clinical Research Center for Oral Disease National Engineering Research Center of Oral Biomaterials and Digital Medical Devices Beijing Key Laboratory of Digital Stomatology Research Center of Engineering and Technology for Computerized Dentistry Ministry of Health NMPA Key Laboratory for Dental Materials Beijing ChinaDepartment of Prosthodontics Peking University School and Hospital of Stomatology National Center of Stomatology National Clinical Research Center for Oral Disease National Engineering Research Center of Oral Biomaterials and Digital Medical Devices Beijing Key Laboratory of Digital Stomatology Research Center of Engineering and Technology for Computerized Dentistry Ministry of Health NMPA Key Laboratory for Dental Materials Beijing ChinaDepartment of Prosthodontics Peking University School and Hospital of Stomatology National Center of Stomatology National Clinical Research Center for Oral Disease National Engineering Research Center of Oral Biomaterials and Digital Medical Devices Beijing Key Laboratory of Digital Stomatology Research Center of Engineering and Technology for Computerized Dentistry Ministry of Health NMPA Key Laboratory for Dental Materials Beijing ChinaDepartment of Stomatology Peking University Third Hospital Beijing ChinaDepartment of Stomatology Beijing Chao‐Yang Hospital Capital Medical University Beijing ChinaDepartment of Prosthodontics Peking University School and Hospital of Stomatology National Center of Stomatology National Clinical Research Center for Oral Disease National Engineering Research Center of Oral Biomaterials and Digital Medical Devices Beijing Key Laboratory of Digital Stomatology Research Center of Engineering and Technology for Computerized Dentistry Ministry of Health NMPA Key Laboratory for Dental Materials Beijing ChinaDepartment of Prosthodontics Peking University School and Hospital of Stomatology National Center of Stomatology National Clinical Research Center for Oral Disease National Engineering Research Center of Oral Biomaterials and Digital Medical Devices Beijing Key Laboratory of Digital Stomatology Research Center of Engineering and Technology for Computerized Dentistry Ministry of Health NMPA Key Laboratory for Dental Materials Beijing ChinaAbstract Nonalcoholic fatty liver disease (NAFLD) encompasses a broad range of conditions, commencing with simple steatosis and progressing to non‐alcoholic steatohepatitis, with the possibility of further deterioration into fibrosis, cirrhosis, and ultimately, hepatocellular carcinoma. Unfortunately, there is currently no approved medication for treating NAFLD‐associated liver steatosis. This underscores the need for improved therapeutic approaches that can modulate lipid metabolism and halt the transition from liver steatosis to chronic liver disease. Our previous studies have demonstrated that apoptotic vesicles (apoVs), which are produced during apoptosis, show great potential in regulating liver homeostasis. However, whether they can ameliorate NAFLD is unknown. In our research, apoVs derived from platelets (PLT‐apoVs) as well as apoVs derived from mesenchymal stem cells (MSC‐apoVs) were used to treat NAFLD. The results showed that PLT‐apoVs exhibited superior effects in diminishing lipid accumulation in liver induced by high‐fat diet than MSC‐apoVs. Through proteomic analysis, we defined and validated apolipoprotein A‐II (APOA2) as a regulator for apoV‐mediated MSC adipogenesis, which could be used as a target to enhance apoV therapeutic potential in the lipid metabolism biomedical field. Owing to the higher expression of APOA2, PLT‐apoVs showed better therapeutic effects than MSC‐apoVs. Our results pave the way to apoV‐based therapy for NAFLD.https://doi.org/10.1002/INMD.20240059apolipoprotein A‐IIapoptotic vesiclesnonalcoholic fatty liver diseaseplatelets |
| spellingShingle | Yuhe Jiang Yike Liao Zeying Wang Lei Zhu Yunsong Liu Ping Zhang Yuan Zhu Wenyue Li Yongsheng Zhou Xiao Zhang Platelet‐derived apoptotic vesicles ameliorate nonalcoholic fatty liver disease by regulating lipid metabolism via apolipoprotein A‐II Interdisciplinary Medicine apolipoprotein A‐II apoptotic vesicles nonalcoholic fatty liver disease platelets |
| title | Platelet‐derived apoptotic vesicles ameliorate nonalcoholic fatty liver disease by regulating lipid metabolism via apolipoprotein A‐II |
| title_full | Platelet‐derived apoptotic vesicles ameliorate nonalcoholic fatty liver disease by regulating lipid metabolism via apolipoprotein A‐II |
| title_fullStr | Platelet‐derived apoptotic vesicles ameliorate nonalcoholic fatty liver disease by regulating lipid metabolism via apolipoprotein A‐II |
| title_full_unstemmed | Platelet‐derived apoptotic vesicles ameliorate nonalcoholic fatty liver disease by regulating lipid metabolism via apolipoprotein A‐II |
| title_short | Platelet‐derived apoptotic vesicles ameliorate nonalcoholic fatty liver disease by regulating lipid metabolism via apolipoprotein A‐II |
| title_sort | platelet derived apoptotic vesicles ameliorate nonalcoholic fatty liver disease by regulating lipid metabolism via apolipoprotein a ii |
| topic | apolipoprotein A‐II apoptotic vesicles nonalcoholic fatty liver disease platelets |
| url | https://doi.org/10.1002/INMD.20240059 |
| work_keys_str_mv | AT yuhejiang plateletderivedapoptoticvesiclesamelioratenonalcoholicfattyliverdiseasebyregulatinglipidmetabolismviaapolipoproteinaii AT yikeliao plateletderivedapoptoticvesiclesamelioratenonalcoholicfattyliverdiseasebyregulatinglipidmetabolismviaapolipoproteinaii AT zeyingwang plateletderivedapoptoticvesiclesamelioratenonalcoholicfattyliverdiseasebyregulatinglipidmetabolismviaapolipoproteinaii AT leizhu plateletderivedapoptoticvesiclesamelioratenonalcoholicfattyliverdiseasebyregulatinglipidmetabolismviaapolipoproteinaii AT yunsongliu plateletderivedapoptoticvesiclesamelioratenonalcoholicfattyliverdiseasebyregulatinglipidmetabolismviaapolipoproteinaii AT pingzhang plateletderivedapoptoticvesiclesamelioratenonalcoholicfattyliverdiseasebyregulatinglipidmetabolismviaapolipoproteinaii AT yuanzhu plateletderivedapoptoticvesiclesamelioratenonalcoholicfattyliverdiseasebyregulatinglipidmetabolismviaapolipoproteinaii AT wenyueli plateletderivedapoptoticvesiclesamelioratenonalcoholicfattyliverdiseasebyregulatinglipidmetabolismviaapolipoproteinaii AT yongshengzhou plateletderivedapoptoticvesiclesamelioratenonalcoholicfattyliverdiseasebyregulatinglipidmetabolismviaapolipoproteinaii AT xiaozhang plateletderivedapoptoticvesiclesamelioratenonalcoholicfattyliverdiseasebyregulatinglipidmetabolismviaapolipoproteinaii |